Matrix metalloproteinase-2, -9, and tissue inhibitor of MMP-2 gene polymorphisms in Taiwanese periodontitis patients

Yu-Feng Hsiao, Li-Chiu Yang, Yu-Shian Chou, Ya-Ping Ho, Ying-Chu Lin, Kun-Yen Ho, Yi-Min Wu, Chi-Cheng Tsai

Institute of Biomedical Nutrition, Hungkuang University, Taichung, Taiwan
Division of Periodontics, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
College of Dental Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
Periodontics, University Hospital and College of Oral Medicine, Chung Shan Medical University, Taichung, Taiwan

Received 27 May 2016; Final revision received 1 July 2016
Available online 9 August 2016

Abstract
Background/purpose: Matrix metalloproteinases (MMPs) and tissue inhibitor of MMPs (TIMPs) have been shown to play an important role in the pathogenesis of tissue destruction in periodontitis. The associations between single nucleotide polymorphisms (SNPs) in the promoter regions of MMP-2, MMP-9, and TIMP-2 genes and the risk of aggressive periodontitis (AgP) and chronic periodontitis (CP) were investigated in a Taiwanese population.

Materials and methods: MMP-2 C-1306T, C-735T, T-790G, and MMP-9 C-1562T and TIMP-2 G-418C SNPs were genotyped by polymerase chain reaction-restriction fragment length polymorphism analysis in 69 patients and 129 patients with AgP and CP, respectively, and 117 periodontal healthy individuals who served as healthy controls (HC). Chi-square test and logistic regression analysis were used to investigate the possible association of genotypes with periodontitis.

Results: No significant differences in the distributions of the C-1306T and C-735T variants between periodontitis and HC were detected. Patients with genotype of MMP-2 -790 TT or T allele of MMP-2-790T/G as compared to genotypes of GT + GG genotypes or G allele, were less susceptible to CP [odds ratio (OR) = 0.50, 95% confidence interval (CI) = 0.25–1.00 and OR = 0.52, 95% CI = 0.28–0.96, respectively]. The frequencies of TIMP-2 G-418C gene polymorphisms in nonsmokers were statistically significantly different among AgP, CP, and HC groups (P = 0.024). The nonalcohol drinking participants with C allele of MMP-9 C-1562T as compared to T allele, were less susceptible to AgP (adjusted OR = 0.4; 95% CI, 0.18–0.90).

* Corresponding author. University Hospital and College of Oral Medicine, Taiwan Chung Shan Medical University, Number 110, Section 1, Jianguo North Road, Taichung City 40201, Taichung, Taiwan.
E-mail address: chchts@csmu.edu.tw (C.-C. Tsai).

http://dx.doi.org/10.1016/j.jds.2016.07.001
1991-7902/Copyright © 2016, Association for Dental Sciences of the Republic of China. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Periodontitis is a multifactorial disease that involves microbial challenge and host responses. Although bacteria are the initial factors for human periodontitis, their impact may be modified by an individual’s predisposition, which can determine the manifestation and progression of the disease. Matrix metalloproteinases (MMPs) play an important role in physiological and pathological events, including the repair and breakdown of connective tissue because of the inflammatory response. Excessive production of MMPs because of genetic polymorphisms may influence the manifestation and development of periodontal diseases.

MMP-2 can broadly break down both type IV collagen and noncollagenous components of extracellular matrix, and also native type collagen type I collagen in the gingival connective tissue matrix. MMP-2 has effects on stimulating cell proliferation and inhibiting apoptosis. MMP-2 also affects fibroblast growth factor-1, leading to the release of the active soluble ectodomain of the receptor; therefore, it has the potential to modulate the mitogenic and angiogetic activities of the fibroblast growth factor. These findings suggest that MMP-2 can contribute not only to tissue destruction but also to tissue repair. Elevated levels of MMP-2 have been reported in gingival crevicular fluid and gingival tissue of periodontitis.

The constitutive and induced expression of MMP-2 is likely to be subjected to regulation by transcription factors. Several single nucleotide polymorphisms (SNPs) in the MMP-2 promoter region have been identified including MMP-2 -1306 C>T (rs2285053), MMP-2 -735 C>T (rs2285053), and MMP-2 -790 T>G (rs243864). A C to T transition located at nucleotides -1306 and a C to T allelic variation located at -735 might disrupt a SP1-binding site and consequently diminish promoter activity. The MMP-2 -790GG genotype was observed to be marginally less frequent in patients with chronic periodontitis (CP).

A large number of molecular epidemiological studies have been performed to evaluate the role of these MMP-2 gene polymorphisms in various tumors. Considering the role of MMP-2 in both remodeling and destruction of extracellular matrix, we hypothesize that MMP-2 genetic variations influencing the transcription or function of this enzyme might contribute to the susceptibility to periodontitis.

MMP-9 (gelatinase-B, 96 kDa gelatinase) is one of the MMPs responsible for the breakdown of type IV collagen and noncollagenous components of the extracellular matrix. In addition, MMP-2—but not MMP-9—is also able to cleave native type I collagen, which is the abundant component of gingival connective tissue matrix. Elevated levels of MMP-9 have been detected in gingival crevicular fluid and gingival tissue of periodontitis patients. A single-base substitution variant in the MMP-9 gene is located at the promoter site at position -1562 relative to the transcription start site where a transition between C and T occurs. The functional polymorphism is characterized with increased mRNA, protein level, and activity in MMP-9 -1562 T allele carriers of MMP-9.

Tissue inhibitor of metalloproteinase-2 (TIMP-2) is particularly important because of its dual functions in terms of regulating MMP-2 activity. It is reasonable to postulate that the polymorphism may downregulate TIMP-2 expression and consequently cause an imbalance between the activities of TIMP-2 and MMP-2, which are believed to have a significant impact on periodontitis development and progression.

Although some reports revealed that the polymorphisms of MMP-2 (-1306 C/T, -735 C/T, and -790 T/G) and TIMP-2 -418 G/C were related to the risk of some diseases, so far reports on the correlation between these polymorphisms and the risk of periodontitis development/susceptibility were rare and showed different results.

Considering the role of MMP-2, MMP-9, and TIMP-2 in both remodeling and destruction of the extracellular matrix, whether genetic variations influencing the transcription or function of these enzymes contribute to the susceptibility to CP and aggressive periodontitis (AgP), we aimed to evaluate the genotype distributions and allele frequencies of MMP-2 -1306C/T, MMP-2 -735C/T, MMP-2 -790T/G, MMP-9 -1562C/T, and TIMP-2 -418G/C genes and their relation to the susceptibility to severe periodontitis in a Taiwanese Han population.

Materials and methods

Study population

A total of unrelated Taiwanese individuals including 129 CP and 69 AgP patients and 117 participants with healthy periodontal condition were recruited from the Department of Periodontology, Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan and Chung Shan Medical University Hospital, Taichung City, Taiwan, between May 2006 and July 2012. All participants underwent clinical and radiographic examination. Medical and dental histories were taken. Current smokers or former smokers who were smoking > 10 cigarettes per day for > 5 years were tagged as the smoking group. Participants who had never smoked were classified as the nonsmoking group. None of the CP and AgP patients and healthy participants had a history or current manifestation of systemic conditions, which could modify the periodontal status including the diseases that have been associated with investigated MMP gene polymorphisms (cancer, cardiovascular diseases, or respiratory diseases) or had transmissible infectious diseases (human immunodeficiency virus, hepatitis). Pregnancy was also...
selected as one of the exclusion criteria for the study. Participants eligible for the study signed the informed consent. The Research Ethics Committee of Kaohsiung Medical University Hospital (KMUH-IRB970384) and Chung Shan Medical University Hospital (CSMUH No. CS09107) approved the study protocol. Periodontitis patients were diagnosed in accordance with the clinical criteria for CP or AgP as established by consensus at the World Workshop in Periodontics in 1999.28

Genomic DNA preparation and quantitation

A 20-mL sample of whole blood was collected into EDTA-coated vacutainer tubes using the standard venipuncture method, then centrifuged at 4°C (1600 g) for 10 minutes. Genomic DNA was extracted from peripheral leukocytes using standard phenol/chloroform extraction techniques, and precipitated by ethanol using the DNA isolation kit (Puregene, Gentra System, Minneapolis, MN, USA) according to the procedure described by Blin and Stafford.29 DNA concentration was determined by spectrophotometry at 280 nm (UV) wavelength and diluted as 10 ng/μL.

Genotyping of MMP-2, MMP-9, and TIMP-2

The SNPs of the genotypes at positions of MMP-2 -1306, MMP-2 -790, MMP-2 -735, MMP-9 -1562, and TIMP-2 -418 from the transcription start site were detected by polymerase chain reaction (PCR) amplification followed by restriction enzyme digestion. The synthetic oligonucleotide primer sequences, PCR conditions for MMP-2, MMP-9, and TIMP-2 restriction fragment length polymorphisms and PCR products are outlined in Table 1.

Statistical analysis

PowerMarker version 3.25 (GlaxoSmithKline, NC, USA) was used to test for deviation of genotype frequencies from Hardy–Weinberg equilibrium. Comparisons of descriptive statistics in the three groups are shown as mean (± standard deviation) and within-group proportions. The χ² test and analysis of variance test were used to compare the proportions and means, respectively, and to evaluate the statistical significance of differences among the three groups. The risk associated with genotype and periodontitis was calculated using simple logistic regression and displayed as the odds ratio (OR) with 95% confidence interval (CI). A multivariate logistic regression was used to assess the relationship of the genotype to disease status while adjusting for the potential confounding effects of age, sex, and smoking status, which were used as independent variables. A P value < 0.05 was considered statistically significant. All data analyses were performed using the statistical package SPSS version 17.0 (SPSS Inc., Chicago, IL, USA).

Results

Overall, 87 CP patients, 69 AgP patients, and 117 healthy controls (HCs) had fulfilled the minimal required sample size for genotyping test. The demographic parameters of the study groups are summarized in Table 2. Significant differences in age, habits of betel quid chewing, smoking, and alcohol drinking were noted among these three groups. No significant differences in the genotype distributions of the MMP-2 C-1306T and C-735T, and MMP-9 C-1562T among periodontitis and control groups were detected in our study (Table 3). There was only a trend of difference in the allele distributions of the MMP-2 T-790G and genotype distributions of TIMP-2 G-418C (Table 3, P = 0.08). The MMP-2 T-790G and TIMP-2 G-418C genotypes in the CP and healthy groups were found in accordance with those expected by the Hardy–Weinberg equilibrium.

Next, the study participants were subcategorized according to their smoking, betel quid chewing, and alcohol drinking habits. Multiple logistic regression analysis was used to evaluate the association of the rare allele-carrying genotypes with periodontal disease susceptibility, while adjusting for modifying factors such as age, sex, and smoking. The logistic regression indicated that TIMP-2 G-

| Gene   | Primers                        | Restriction enzyme | PCR conditions for MMP-2, MMP-9, and TIMP-2 restriction fragment length polymorphisms. |
|--------|--------------------------------|-------------------|----------------------------------------------------------------------------------|
| MMP-2  | 5'-CTTCTGAGGCTCTTACTGA-3' (forward) | Xsp1              | 188 ± 162 + 26 bp (CT); 188 bp (CC)                                             |
|        | 5'-CTGAGCTAAGCTAAGCTAAGCT-3' (reverse) |                  | 162 ± 26 bp (TT)                                                                |
|        | 95°C, 10 min, 35 cycles then 95°C, 45 s then 55°C, 45 s; 72°C, 45 s |                  |                                                                                  |
| MMP-2  | 5'-GGGTCTTTTGTGACCTCGATC-3' (forward) | PvuI              | 118 ± 99 + 19 bp (TG); 118 bp (TT)                                            |
|        | 5'-GGTTAATAGGCTGACCTG-3' (reverse)     |                  | 99 ± 19 bp (GG)                                                               |
|        | 95°C, 10 min, 40 cycles then 95°C, 45 s then 55°C, 45 s; 72°C, 45 s |                  |                                                                                  |
| MMP-735C/T | 5'-ATAGGGTAAACCTCCCCACATT-3' (forward) | Hinfl             | 300 ± 254 + 46 bp (CT); 300 bp (CC)                                            |
|         | 5'-GGTTAATAGGCTGACCTG-3' (reverse)     |                  | 254 ± 46 bp (TT)                                                              |
|        | 95°C, 10 min, 40 cycles then 95°C, 45 s then 55°C, 45 s; 72°C, 45 s |                  |                                                                                  |
| TIMP-2  | 5'-CGTTCCAGTCTGGCCTGCA-3' (forward)   | BsoBI             | 230 + 51 + 23 bp (GG); 230 + 51 bp (CC)                                         |
|        | 5'-CTTCCAGCTGACTTGGAG-3' (reversed)    |                  | 253 + 51 + 23 bp (CC)                                                         |
|        | 94°C, 4 min, 35 cycles then 94°C, 1 min, then 56°C 45 s; 72°C, 45 s |                  |                                                                                  |
| MMP-9  | 5'-GGGATAATTTGGCTCTGCTCA-3' (forward)  | Sphol              | 436 ± 194 + 242 bp (CT)                                                        |
|        | 5'-CCATGGAACCACTGAAAG-3' (reversed)    |                  |                                                                                  |
Table 2  Demographic data of participants in healthy control (HC), aggressive periodontitis (AgP), and chronic periodontitis (CP) groups.

|            | HC          | AgP         | CP          | \(\chi^2\) | P       |
|------------|-------------|-------------|-------------|-------------|---------|
| Age (mean ± SD) | 45.5 ± 11.3 | 39.0 ± 10.1 | 50.8 ± 8.6  | 31.48       | 0.000   |
| Sex        |             |             |             |             |         |
| Male       | 57 (48.7)   | 41 (59.4)   | 74 (57.4)   | 2.68        | 0.260   |
| Female     | 60 (51.3)   | 28 (40.6)   | 55 (42.6)   |             |         |
| Habit      |             |             |             |             |         |
| BQ chewing |             |             |             |             |         |
| Yes        | 8 (6.8)     | 10 (14.5)   | 28 (21.7)   | 10.88       | 0.004   |
| No         | 109 (93.2)  | 59 (85.5)   | 101 (78.3)  |             |         |
| Smoking    |             |             |             |             |         |
| Yes        | 20 (17.1)   | 26 (37.7)   | 51 (39.5)   | 16.47       | 0.000   |
| No         | 97 (82.9)   | 43 (62.3)   | 78 (60.5)   |             |         |
| Al drinking|             |             |             |             |         |
| Yes        | 30 (25.6)   | 29 (42.0)   | 65 (50.4)   | 16.00       | 0.000   |
| No         | 87 (74.4)   | 40 (58.0)   | 64 (49.6)   |             |         |

\(\chi^2\) = chi-square; P = probability.

Al drinking = alcohol drinking; BQ chewing = betel quid chewing; SD = standard deviation.

Table 3  Association of MMP-2-1306, -790, and -735, MMP-9-1562 and TIMP2 418 genotypes, and allele with healthy control (HC), aggressive periodontitis (AgP), and chronic periodontitis (CP) groups.

| Genotype       | HC          | AgP         | CP          | \(\chi^2\) | P       |
|----------------|-------------|-------------|-------------|-------------|---------|
| MMP-2-1306     |             |             |             |             |         |
| CC             | 105 (89.7)  | 62 (89.9)   | 114 (88.4)  | 1.49        | 0.83    |
| CT             | 12 (10.3)   | 7 (10.1)    | 14 (10.9)   |             |         |
| TT             | 0 (0.0)     | 0 (0.0)     | 1 (0.8)     |             |         |
| C allele       | 222 (94.9)  | 131 (94.9)  | 242 (93.8)  | 0.35        | 0.84    |
| T allele       | 12 (5.1)    | 7 (5.1)     | 16 (6.2)    |             |         |
| MMP-2-735      |             |             |             |             |         |
| CC             | 57 (48.7)   | 39 (56.5)   | 75 (58.1)   | 2.98        | 0.56    |
| CT             | 48 (41.0)   | 26 (37.7)   | 44 (34.1)   |             |         |
| TT             | 12 (10.3)   | 4 (5.8%)    | 10 (7.8)    |             |         |
| C allele       | 162 (69.2)  | 104 (75.4)  | 194 (75.2)  | 2.71        | 0.26    |
| T allele       | 72 (30.8)   | 34 (24.6)   | 64 (24.8)   |             |         |
| MMP-2-790      |             |             |             |             |         |
| TT             | 98 (83.8)   | 52 (75.4)   | 95 (73.6)   | 5.80        | 0.21    |
| GT             | 18 (15.4)   | 17 (24.6)   | 31 (24.0)   |             |         |
| GG             | 1 (0.9)     | 0 (0.0)     | 3 (2.3)     |             |         |
| T allele       | 214 (91.5)  | 121 (87.7)  | 219 (84.9)  | 5.00        | 0.08    |
| G allele       | 20 (8.5)    | 17 (12.3)   | 39 (15.1)   |             |         |
| TIMP-2-418     |             |             |             |             |         |
| GG             | 73 (62.4)   | 48 (69.6)   | 94 (72.9)   | 8.51        | 0.08    |
| GC             | 44 (37.6)   | 19 (27.5)   | 31 (24.0)   |             |         |
| CC             | 0 (0.0)     | 2 (2.9)     | 4 (3.1)     |             |         |
| G allele       | 188 (81.7)  | 114 (83.8)  | 219 (84.9)  | 0.89        | 0.64    |
| C allele       | 42 (18.3)   | 22 (16.2)   | 39 (15.1)   |             |         |
| MMP-9-1562     |             |             |             |             |         |
| CC             | 90 (76.9)   | 48 (69.6)   | 96 (74.4)   | 1.48        | 0.83    |
| CT             | 28 (21.4)   | 19 (27.5)   | 31 (24.0)   |             |         |
| TT             | 2 (1.7)     | 2 (2.9)     | 2 (1.6)     |             |         |
| C allele       | 205 (87.6)  | 115 (83.3)  | 223 (86.4)  | 1.35        | 0.51    |
| T allele       | 29 (12.4)   | 23 (16.7)   | 35 (13.6)   |             |         |

MMP = matrix metalloproteinase; TIMP, tissue inhibitor of MMPs.
418C gene polymorphisms in nonsmokers were statistically significantly different among AgP, CP, and HC groups \( (P = 0.024, \text{ Table 4}) \); the participants with MMP-2 -970 TT genotypes and T allele as compared to GT ÷ GG genotypes and G allele, were less susceptible to CP \( (\text{adj. OR } = 0.50, 95\% \text{ CI } = 0.25 \text{ to } 1.00 \text{ and adj. OR } = 0.52, 95\% \text{ CI } = 0.23 \text{ to } 0.96, \text{ respectively; Table 5}) \), and the nonalcohol drinking participants with MMP-9-1562 C allele as compared to those with T allele, were less susceptible to AgP but not to CP \( (\text{adj. OR } = 0.40, 95\% \text{ CI } = 0.18 \text{ to } 0.90; \text{ Table 6}) \).

### Discussion

The human MMP-2 gene exhibits sequence variations, and several functional SNPs in the MMP-2 promoter have been described.\(^{30,31}\) A C ÷ T polymorphism located at nucleotide -1306 site disrupts an Sp1 regulatory element, and the T allele thus has a strikingly lower promoter activity.\(^{31}\) The -1306C ÷ T and -735C ÷ T polymorphisms are in a linkage disequilibrium and the T-1306C ÷ T-735 haplotype displays an even lower promoter activity and mRNA expression compared with the haplotype consisting of only one T allele at the -1306 or -735 site, indicating an interactive effect of these two SNPs on MMP-2 transcriptional function.\(^{31}\) The study observed an increased risk of the cancer associated not only with the -1306C allele but also with the -735C allele; furthermore, an even greater association was observed between elevated risk of developing esophageal squamous cell carcinoma (SCC) and C-1306 and C-735-allele containing haplotypes.\(^{32}\) A contribution of MMP-2 C-1306 and C-735-allele containing haplotypes, alone or in combination with smoking, to the risk of developing lung cancer in a case-control study has been reported.\(^{33}\) A joint effect between the MMP-2 promoter polymorphisms and tobacco smoking was evident. The -1306CC and -735CC genotypes or the C-1306C ÷ C-735C haplotypes were significantly associated with lung cancer risk in nonsmokers; however, the risk was markedly elevated in smokers, particularly heavy smokers, suggesting an additive gene-smoking interaction. Tobacco smoking is an established etiological factor for lung cancer; therefore,
this gene—smoking interaction is biologically plausible. A higher risk of lung cancer among smokers who carried the susceptible genotypes or haplotypes may be attributed to many transformed or preinvasive lung cells caused by tobacco carcinogens, which in turn increases the possibility that one of these cells will become an invasive tumor under the condition of higher lifetime expression of MMP-2. In addition, MMP expression can be induced by smoking.32,34 Given these conditions, it would be expected that individuals who smoked and carried the /C01306CC and /C0735CC genotypes or the C/C01306eC732 haplotype were more susceptible to developing lung cancer. A trend to decreased frequency of the MMP-2-790 GG homozygotes was observed in patients with CP compared to HC (P < 0.036, corrected P > 0.05).29

Table 5  Logistic regression analysis of the associations of the genotypes and allele frequencies of MMP-2 -1306, -790, and -735, MMP-9 -1562, and TIMP-2 -418 genes, and chronic periodontitis (CP) risks.

| Genotype    | HC  | CP  | Crude OR (95% CI) | Adjusted ORa (95% CI) |
|-------------|-----|-----|-------------------|-----------------------|
|             | n=117 (%) | n=129 (%) |                 |                       |
| MMP-2-1306  |     |     |                   |                       |
| CT/TT       | 12 (10.3) | 15 (11.6) | 1                 | 1                     |
| CC          | 105 (89.7) | 114 (88.4) | 0.87 (0.39–1.94) | 0.94 (0.39–2.26)     |
| T allele    | 12 (5.1)  | 16 (6.2)  | 1                 | 1                     |
| C allele    | 222 (94.9) | 242 (93.8) | 0.82 (0.38–1.77) | 0.87 (0.38–2.00)     |
| MMP-2-735   |     |     |                   |                       |
| TT          | 12 (10.3) | 10 (7.8)  | 1                 | 1                     |
| CT          | 48 (41.0) | 44 (34.1) | 1.1 (0.43–2.80)  | 1.18 (0.42–0.34)     |
| CC          | 57 (48.7) | 75 (58.1) | 1.58 (0.64–3.91) | 1.78 (0.64–4.93)     |
| T allele    | 72 (30.8) | 64 (24.8) | 1                 | 1                     |
| C allele    | 162 (69.2) | 194 (75.2) | 1.35 (0.91–2.00) | 1.41 (0.91–2.18)     |
| MMP-2-790   |     |     |                   |                       |
| GT/GG       | 19 (16.2) | 34 (26.4) | 1                 | 1                     |
| TT          | 98 (83.8) | 95 (73.6) | 0.54 (0.29–1.02) | 0.50* (0.25–1.00)    |
| G allele    | 20 (8.5)  | 39 (15.1) | 1                 | 1                     |
| T allele    | 214 (91.5) | 219 (84.9) | 0.53* (0.30–0.93) | 0.52* (0.28–0.96)    |
| TIMP-2-418  |     |     |                   |                       |
| GC/CC       | 44 (37.6) | 35 (27.1) | 1                 | 1                     |
| GG          | 73 (62.4) | 94 (72.9) | 1.62 (0.94–2.78) | 1.46 (0.81–2.63)     |
| G allele    | 188 (81.7) | 219 (84.9) | 1                 | 1                     |
| C allele    | 42 (18.3) | 39 (15.1) | 0.8 (0.50–1.29) | 0.9 (0.53–1.51)      |
| MMP-9-1562  |     |     |                   |                       |
| TT          | 2 (1.7)  | 2 (2.9)  | 1                 | 1                     |
| CT          | 28 (21.4) | 19 (27.5) | 1.24 (0.16–9.44) | 0.94 (0.11–7.91)     |
| CC          | 90 (76.9) | 48 (69.6) | 1.07 (0.15–7.73) | 0.99 (0.13–7.83)     |
| T allele    | 29 (12.4) | 35 (13.6) | 1                 | 1                     |
| C allele    | 205 (87.6) | 223 (87.1) | 0.9 (0.53–1.53) | 1.04 (0.58–1.83)     |

* P < 0.05.
HC = healthy control; MMP = matrix metalloproteinase; OR = odds ratio; TIMP, tissue inhibitor of MMPs.

a Adjustment for age, sex, and habits of betel quid chewing, alcohol drinking, and smoking.

Although not significant (P = 0.06), higher T allele carriage in the healthy group than in the CP group was
in agreement with these previous Turkish population studies.26,37 Moreover, logistic regression analysis revealed an adjusted OR of 0.36, indicating a decreased susceptibility to CP in T allele carriers. Genotype distribution and rare allele carriage of \( \text{MMP-9 -1562 C/T} \) gene polymorphism in a Turkish population seem to be in contrast to the probable linkage between MMP-9 -1562 T allele carriage and increased MMP-9 function and consequently to the periodontal destruction. These results are also in contradiction to the results of previous studies in other populations.36 The higher frequency and carriage of T allele in the healthy group might be of importance in supporting the recent findings indicating defensive anti-inflammatory properties of MMP-9.36 In addition, it should be kept in mind that MMP-9 activity is also modulated by activation of the proenzyme and by regulation of MMP inhibitors.

In conclusion, a significant difference (\( P = 0.024 \)) in the frequencies of TIMP-2 G-418C polymorphisms among non-smokers in the AgP, CP, and HC groups were observed. However, the logistic regression analysis revealed that MMP-2 -790TT genotype and T allele might be a protective factor for CP. The MMP-9-1562 C allele was found to be a significant protective factor for AgP after adjustment for age, sex, betel quid chewing, and smoking in nonalcohol drinking individuals. Additional multicenter studies are necessary to clarify whether genetic variations within the MMP genes contribute to interindividual differences in susceptibility to severe CP and AgP.

**Conflicts of interest**

The authors have no conflicts of interest relevant to this article.

**Acknowledgments**

This study was supported by grants from the NSC (98-2314-B-040-020 and 99-2628-B-040-001) Taiwan, R.O.C. and from the College of Oral Medicine, Chung Shan Medical University, Taichung, Taiwan, R.O.C.

**References**

1. Chen D, Wang Q, Ma ZW, et al. MMP-2, MMP-9 and TIMP-2 gene polymorphisms in Chinese patients with generalized aggressive periodontitis. J Clin Periodontol 2007;34:384–9.
2. Ingman T, Tervahartiala T, Ding Y, et al. Matrix metalloproteinases and their inhibitors in gingival crevicular fluid

---

**Table 6** Associations of genotypes and allele frequencies of MMP-2 -1306, -790, and -735, MMP-9 -1562 and TIMP-2 -418 genes, and AgP risks in nonalcohol-drinking participants using logistic regression analysis.

| Genotype      | HC n = 87 (%) | AgP n = 40 (%) | Crude OR (95% CI) | Adjusted OR<sup>a</sup> (95% CI) |
|---------------|---------------|----------------|-------------------|----------------------------------|
| **MMP-2-1306**|               |                |                   |                                  |
| CT/TT         | 7 (8.0)       | 3 (7.5)        | 1.00              | 1.00                             |
| CC            | 80 (92.0)     | 37 (92.5)      | 1.08 (0.26–4.41)  | 0.88 (0.19–3.98)                 |
| T allele      | 7 (4.1)       | 3 (3.7)        | 1.00              | 1.00                             |
| C allele      | 165 (95.9)    | 77 (96.3)      | 1.08 (0.27–4.27)  | 0.86 (0.20–3.72)                 |
| **MMP-2-735** |               |                |                   |                                  |
| TT            | 9 (10.4)      | 2 (5.0)        | 1.00              | 1.00                             |
| CT            | 31 (35.6)     | 15 (37.5)      | 2.18 (0.42–11.36) | 1.96 (0.34–11.30)                |
| CC            | 47 (54.0)     | 23 (57.5)      | 2.20 (0.44–11.03) | 2.06 (0.38–11.26)                |
| T allele      | 49 (28.5)     | 19 (23.7)      | 1.00              | 1.00                             |
| C allele      | 123 (71.5)    | 61 (76.3)      | 1.26 (0.68–2.32)  | 1.26 (0.65–2.43)                 |
| **MMP-2-790** |               |                |                   |                                  |
| GT/GG         | 12 (13.8)     | 9 (22.5)       | 1.00              | 1.00                             |
| TT            | 75 (86.2)     | 31 (77.5)      | 0.55 (0.21–1.44)  | 0.63 (0.23–1.75)                 |
| G allele      | 13 (7.6)      | 9 (11.2)       | 1.00              | 1.00                             |
| T allele      | 159 (92.4)    | 71 (88.8)      | 0.64 (0.26–1.56)  | 0.69 (0.27–1.79)                 |
| **TIMP-2-418**|               |                |                   |                                  |
| GC/CC         | 32 (36.8)     | 11 (27.5)      | 1.00              | 1.00                             |
| GG            | 55 (63.2)     | 29 (72.5)      | 1.53 (0.68–3.48)  | 1.73 (0.71–4.22)                 |
| G allele      | 140 (82.4)    | 68 (85.0)      | 1.00              | 1.00                             |
| C allele      | 30 (17.6)     | 12 (15.0)      | 0.80 (0.39–1.66)  | 0.72 (0.33–1.56)                 |
| **MMP-9-1562**|               |                |                   |                                  |
| CT/TT         | 18 (20.7)     | 14 (35.0)      | 1.00              | 1.00                             |
| CC            | 69 (79.3)     | 26 (65.0)      | 0.48 (0.21–1.11)  | 0.40 (0.16–1.02)                 |
| T allele      | 19 (11.0)     | 16 (20.0)      | 1.00              | 1.00                             |
| C allele      | 153 (89.0)    | 64 (80.0)      | 0.49 (0.24–1.01)  | 0.40* (0.18–0.90)                |

<sup>a</sup> Adjustments for age, sex, and habits of betel-quid chewing and smoking.

<sup>P < 0.05.</sup>

AgP = aggressive periodontitis group; CI = confidence interval; HC = healthy control group; MMP = matrix metalloproteinase; OR = odds ratio; TIMP, tissue inhibitor of MMPs.
and saliva of periodontitis patients. J Clin Periodontol 1996;23: 1127–32.

3. Lee W, Aitken S, Sodek J, McCullough CAG. Evidence of a direct relationship between neutrophil collagenase activity and periodontal tissue destruction in vivo: role of active enzyme in human periodontitis. J Periodontol Res 1995;30:23–33.

4. Uitto VJ, Overall CM, McCulloch C. Proteolytic host cell en-
zymes in gingival crevicular fluid. Periodontol 2000 2003;31: 77–104.

5. Aimes RT, Quigley JP. Matrix metalloproteinase-2 is an inter-
stitial collagenase. Inhibitor-free enzyme catalyzes the cleav-
age of collagen fibrils and soluble native type I collagen generating the specific 3/4 and 1/4-length fragments. J Biol Chem 1995;17:5872–6.

6. Levis E, Fridman R, Miao HQ, Ma YC, Yayan A, Voldavsky I. Matrix metalloproteinase-2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci U S A 1996;93:7069–74.

7. Soell N, Elkaim R, Tenenbaum H, Cathepsin C. Matrix metal-
loproteinases, and their tissue inhibitors in gingiva and gingival crevicular fluid from periodontitis-affected patients. J Dent Res 2002;81:174–8.

8. Ejejil AL, Igondjo-Tchen S, Ghomrasseni S, Pellat B, Godeau G, Gogly B. Expression of matrix metalloproteinases (MMPs) and inhibitors of metalloproteinases (TIMPs) in healthy and diseased human gingiva. J Periodontol 2003;74:188–95.

9. Bia J, Sun T. Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloprotei-

nase-2) promoter. Mol Cell Biol 1977;17:6360–8.

10. Qin H, Sun Y, Benveniste EN. The transcriptional factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglia cells. J Biol Chem 1999;274:19130–7.

11. Price SJ, Greaves DR, Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcrip-
tional regulation. J Biol Chem 2000;276:7549–58.

12. Vasku V, Vasku A, Tschoplova S, Holla IL, Fassmann A, et al. Genetic variations in the promoter of matrix metalloproteinase-2 and lung cancer susceptibility. J Periodontol 2003;74:1003.

13. Bubnik V, Vasku A, Tschoplova S, Holla IL, Fassmann A, et al. Genetic variations in the promoter of matrix metalloproteinase-2 and lung cancer susceptibility. J Periodontol 2003;74:1003.

14. Yu C, Zhou Y, Miao X, Xiong P, Tan W, Lin D. Functional hap-
optotypes in the promoter of matrix metalloproteinase-2 promoter predict the occurrence and metastasis of esophageal cancer. Cancer Res 2004;64:7622–8.

15. Holla LI, Fassmann A, Vasku A, et al. Genetic variations in the human gelatinase A (MMP-2) promoter are not associated with susceptibility to, and severity of, chronic periodontitis (CP). J Periodontol 2005;76:1056–60.

16. Wu CY, Wu MS, Chen YJ, et al. Clinical pathological significance of MMP-2 and TIMP-2 genotypes in gastric cancer. Eur J Cancer 2007;43:799–808.

17. Xing D, Tan W, Lin D. Genetic polymorphisms and susceptibility to esophageal cancer among Chinese population (review). Oncol Rep 2003;10:1615–23.

18. Kadonaga JT, Carner KR, Masiarz FR, Tjian R. Isolation of CDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain. Cell 1987;51:1079–90.

19. Turner J, Crossley M. Mammalian Kruppel-like transcription factors: more than just a pretty finger. Trends Biochem Sci 1999;24:167–7.

20. Reynolds JJ. Collagenases and tissue inhibitors of metal-
loproteinases: a functional balance in tissue degradation. Oral Dis 1996;2:70–6.